Jazz Pharmaceuticals plc - JAZZ
About Gravity Analytica
Recent News
- 10.02.2025 - FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
- 10.02.2025 - FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
- 09.22.2025 - Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
- 09.22.2025 - Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
- 09.09.2025 - Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
- 09.09.2025 - Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
- 09.03.2025 - Jazz Pharmaceuticals at 2025 Wells Fargo Healthcare Conference
- 09.03.2025 - Jazz Pharmaceuticals at 2025 Wells Fargo Healthcare Conference
- 08.27.2025 - Modeyso Investor Webcast
- 08.27.2025 - Modeyso Investor Webcast